GLP-1 Atlas

Atlas / Countries / Denmark

Denmark

3.9researched

A large, sophisticated, fully cash-pay DTC market, and the one Nordic market with a genuinely domestic category leader rather than a pan-European one. You can never own the pharmacy end, because Denmark kept its pharmacist-only concession system under apotekerloven §15, and that turns out to be the moat: Aposund now runs in-person weighing at more than 170 physical pharmacy counters in partnership with Danmarks Apotekerforening, at 140 DKK per four weeks, a price no pure-digital entrant can match. Marketing is the hardest problem here, because Denmark bans video marketing of health services off your own site regardless of whether the drug is named.

Population
6m
Currency
DKK
Region
Nordic Europe
Updated
2026-08-23
01

The six axes

Five is always better for an operator. Hover a label for the question it answers.

OwnershipApotekerloven grants the apoteksbevilling personally to a qualified pharmacist. Denmark did not follow Sweden (2009) or Norway (2001) into deregulation.
Remote prescribingVideo-based DTC prescribing to new patients is established and openly marketed by Embla, Sikkert Vægttab, Junia, Velform and others, on the national FMK/e-recept rails.
Rx mail orderDanish pharmacies may sell and deliver Rx medicines online under Lægemiddelstyrelsen oversight with the mandatory EU green logo.
Advertising roomMarked down, because Denmark runs a SECOND regime with no German analogue and it closes the loophole Juniper Germany relies on. Beyond the ordinary lægemiddellov §64 to §66 ban on advertising prescription medicines to the public, lov om markedsføring af sundhedsydelser makes marketing a health service in video form unlawful anywhere except the provider’s own website, whether or not any drug is named. Meta and YouTube video creative is therefore illegal here even with the molecule withheld. Danish law professor Kent Kristensen put it plainly on the Embla influencer brief: Man slipper ikke uden om de skærpede krav blot ved ikke at nævne medicinen. The advertising definition also expressly binds third parties with no link to the marketing authorisation holder and no financial interest, and breach of §66 carries a fine or up to four months in prison.
Cash-pay marketNo general public tilskud for obesity GLP-1s; Wegovy was refused again on 10 July 2025. Sygeforsikringen Danmark ended general weight-loss-drug coverage on 1 January 2024.
Market size58,873 Danes were in Wegovy treatment by late June 2023 and growth continued; regional semaglutide spend was projected around 1.1bn DKK for 2023. The four largest private clinics self-report roughly 46,000 patient courses started, of which Fit for Livet claims 32,000.
02

How it works here

Ownership [1]

Apotekerloven, administered by Lægemiddelstyrelsen: "Et apotek drives af en privatperson – apotekeren – der har fået bevilling fra Lægemiddelstyrelsen til at drive apotek et bestemt sted." The licence is a personal grant tied to a qualified pharmacist. A 2024 consultation response from Danmarks Apotekerforening indicates incremental reform is under discussion, but no deregulation has been enacted.

A foreign founder cannot acquire or control a Danish apotek. Full stop.

The model that actually runs here [1][2]

Every Danish operator uses the same shape: a telehealth clinic staffed by Danish-authorised physicians prescribes via e-recept, and an existing independent apotek dispenses and mails. No pharmacy ownership is involved.

Sikkert Vægttab runs a fixed physician team, video consultations, four-weekly follow-up and a money-back guarantee if there is no weight loss in three months, charging 299 DKK per four weeks in consultation fees plus 855–4,500 DKK/month for the drug. Embla prices Wegovy at 1,283–2,295 DKK/month by dose plus a 995 DKK monthly membership.

Reimbursement and the advertising climate [1][2][3]

On 10 July 2025 Lægemiddelstyrelsen and Medicintilskudsnævnet again refused general conditional tilskud for Wegovy, even for the narrow adolescent severe-obesity subgroup, citing a daily cost of 82.02 DKK, no dedicated trial data for that group, and more than 60% weight regain within 48 weeks of stopping.

On the marketing side, Novo Nordisk's national menopause-targeted "talk to your doctor about weight-loss treatment" campaign drew criticism from Dansk Selskab for Almen Medicin and the medical association; Lægemiddelstyrelsen initially found it lawful, but Novo paused the campaign on 7 November 2025. DR separately reported experts alleging extensive legal violations by private weight-loss clinics. In Novo's home market the political temperature around this category is higher than the letter of the law suggests.

03

Who is already there

NameModelPrice
Fit for LivetOwn doctors, nurses and dietitians. Any pharmacy dispenses. The Danish category leader.299 DKK / 4 weeks, medicine separate
Aposund (Medicals ApS)In-person weighing at 170+ physical pharmacies with Danmarks Apotekerforening. Names no molecule at all.140 DKK / 4 weeks
Sikkert Vægttab (Rinnovo Medical)Clinic prescribes, any pharmacy. 74 brand-named URLs, the most in the Nordics.299 DKK / 4 weeks, drug 855 to 4,500 DKK
Endolet I/SLed by an endocrinologist with a PhD on GLP-1 treatment. The only operator offering physical attendance.250 DKK / month
EmblaDanish digital weight-loss clinic; €10m raised in 2023, UK entry in 2023Wegovy 1,283–2,295 DKK/month plus 995 DKK membership
Sikkert VægttabVideo consultations, fixed physician team, four-weekly follow-up, money-back guarantee299 DKK/4 weeks plus drug cost
Junia, Velform, Diætisthuset, Fit For Livet, mitvaegttab.dkMembership plus drug-cost telehealth clinics with Danish-licensed physiciansn/a
04

Routes in, and walls

What works viable

  • Establish a Danish (or EU-passportable) telehealth clinic staffed by Danish-authorised physicians, prescribe via e-recept, and fulfil through an existing independent apotek's mail-order arm.

What does not blocked

  • Acquiring or controlling a Danish pharmacy. The bevilling is personal and pharmacist-only.
  • Anything resembling branded Rx-drug promotion to consumers, the political climate here is less forgiving than the statute.
05

How to make it work

The recommended entry path for a non-pharmacist operator running an own brand with a partner pharmacy. Read it against the six axes above, not instead of them.

partner

Run a Danish-authorised clinic, prescribe into e-recept, let any pharmacy dispense, and put no video marketing anywhere except your own website.

You can never own the pharmacy end. Apotekerloven section 15 reserves licences to natural persons holding a pharmaceutical degree, though it does accept equivalent foreign degrees, so this is a structural wall rather than a nationality one. Everything else about Denmark is good: prescribing is the most liberal in the atlas, the market is fully cash-pay, and it is the one Nordic market with a genuinely domestic category leader rather than a pan-European one. But the advertising regime is the hardest in Europe.

  1. Stand up the clinic with Danish-authorised doctors, nurses and dietitiansFit for Livet does exactly this and is profitable at 8.8m DKK net on 31 staff.
  2. Prescribe into e-recept and let the patient collect anywhereThere is no captive pharmacy model in Denmark and you do not need one. The leaders link out to the regulator’s own list of approved online retailers.
  3. Delete video from every channel except your own websiteLov om markedsføring af sundhedsydelser makes marketing a health service in video form unlawful anywhere else, whether or not you name a drug. Meta and YouTube creative is illegal here even with the molecule withheld. This closes the naming-abstention loophole that works in Germany.
  4. Assume Styrelsen for Patientsikkerhed will inspect youIt ran a named campaign on digital weight-loss providers and has opened roughly 500 cases in three years. Write to your GP as a matter of course; the påbud against Klinik Øregaard turned on zero of about 200 patient courses having information passed to the patient’s own doctor.
  5. Price against Aposund, not against the digital playersAposund runs in-person weighing at more than 170 pharmacy counters with the pharmacists’ own trade association at 140 DKK per four weeks. You cannot beat that on price or on verification quality.
What kills it

Aposund. It has taken the one asset a foreign entrant cannot own, the physical pharmacy counter, turned it into a biometric verification layer, and priced below what a pure-digital competitor can sustain.

Rough effort

Low capital, fast. The real cost is giving up video acquisition, which is most of the category’s playbook everywhere else.

06

What has happened

2022-12
Wegovy launches in Denmark.
2024-01-01
Sygeforsikringen Danmark ends general weight-loss-drug coverage.
2024-11-25
Ozempic tilskud criteria tightened for the diabetes indication.
2025-07-10
Lægemiddelstyrelsen again refuses general conditional tilskud for Wegovy.
2025-11-07
Novo Nordisk pauses its criticised weight-loss awareness campaign.
2026-07-15
EU authorises the oral Wegovy pill; no Danish launch date found.
07

What we could not establish

Kept visible on purpose. These are the gaps a decision would have to close.

  • What did the DR investigation into private weight-loss clinics actually find? The full article was inaccessible.
  • Did ENLI issue any formal ruling on the Novo campaign, or was the pause purely voluntary?
  • What is the status of the 2024 apotekerloven amendment proposal?
08

Sources

Every non-obvious claim above links here. Confidence tags are applied strictly.

Apoteker: bevilling og driftLægemiddelstyrelsenverified
Wegovy får ikke generelt klausuleret tilskudLægemiddelstyrelsen · 2025-07-10verified
Wegovy Pris 2025Embla · 2025unverified
Novo Nordisk sætter kritiseret kampagne i beroKristeligt Dagblad · 2025-11-07secondary